HydroxyTyrosol / selectivity Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱
Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).
Hydroxytyrosol is potent against CSC phenotypes.

Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)

Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS tone / lipid peroxidation ↓ (low–mod dose); ↑ (high concentration only) P→R Antioxidant; membrane protection Catechol scavenger; at higher concentrations may induce pro-oxidant stress in tumors (model-dependent).
2 NRF2 axis ↑ (context-dependent) R→G Endogenous antioxidant induction ↑ HO-1/NQO1; protective in normal tissues; could support tumor stress resistance (context-dependent).
3 NF-κB / COX-2 inflammation R→G Anti-inflammatory Reduces pro-tumor inflammatory signaling; consistent with Mediterranean diet data.
4 Mitochondrial function ↔ / ↓ proliferation (model-dependent) ↑ (protective) R→G Bioenergetic stabilization Reported support of mitochondrial integrity in normal cells; may impair cancer cell proliferation via metabolic stress.
5 Apoptosis (caspase activation) ↑ (high concentration only) ↔ / ↓ R→G Pro-apoptotic in select tumors Observed at supra-physiologic exposures in vitro.
6 Ferroptosis axis ↓ (anti-lipid-ROS bias) P→R Inhibits lipid oxidation Strong antioxidant property may counter ferroptotic strategies (context-dependent).
7 Clinical Translation Constraint Exposure limitations Rapid metabolism; plasma free HT lower than many in-vitro doses; best considered dietary adjunct.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 EMT (Epithelial–Mesenchymal Transition) ↓ (model-/dose-dependent) R→G Reduces EMT-associated transcription (e.g., Snail, Twist) Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.
2 CSC markers (CD44+/CD24) ↓ (model-dependent) G Reduces stemness-associated phenotype Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.
3 Notch signaling ↓ (model-dependent) R→G Stemness pathway inhibition Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.
4 HIF-1α / hypoxia-driven stemness ↓ (preclinical) R→G Suppresses hypoxia adaptation Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.
5 Tumor-type specificity Breast, Melanoma, Gastric (preclinical) CSC-like cell sensitivity Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / neuronal membrane protection P Neuroprotective antioxidant Protects against oxidative membrane injury; aligns with AD oxidative stress hypothesis.
2 NRF2 activation R→G Endogenous antioxidant upregulation Supports neuronal resilience under oxidative stress.
3 Neuroinflammation (NF-κB) R→G Microglial modulation Reduces pro-inflammatory cytokines in models.
4 Mitochondrial integrity R→G Bioenergetic stabilization Improves mitochondrial function in neuronal models; may reduce apoptotic susceptibility.
5 Aβ toxicity modulation ↓ (preclinical) G Reduces amyloid-induced oxidative injury Animal/cell evidence; limited direct human AD trials.
6 Clinical Translation Constraint Dietary-level evidence Human data strongest for Mediterranean diet patterns; isolated HT supplementation lacks large AD RCTs.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr



selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability


Scientific Papers found: Click to Expand⟱
4637- HT,    Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells
- in-vitro, Nor, RWPE-1 - in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3
selectivity↑, TumCMig↓, p‑Akt↓, ROS↑, CSCs↓, CD44↓, TumCP↓,
4638- HT,    Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation
- in-vitro, CRC, DLD1 - NA, NA, 1-
selectivity↑, ROS↑, Akt↑, FOXO3↓, Apoptosis↑,
4639- HT,    Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, p27↑, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, p‑Akt↓, p‑STAT3↓, NF-kB↓, AR↓, ROS↑, *BioAv↓, *toxicity∅,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↓, 1,   NOX4↑, 1,   ROS↑, 4,   SIRT3↓, 1,   SOD2↓, 1,  

Mitochondria & Bioenergetics

MMP↓, 2,   MPT↑, 1,  

Core Metabolism/Glycolysis

FASN↓, 1,   PPARγ↑, 1,  

Cell Death

Akt↓, 2,   Akt↑, 1,   p‑Akt↓, 2,   Apoptosis↑, 3,   BAD↑, 1,   Bak↑, 1,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 2,   Casp9↑, 2,   Cyt‑c↑, 1,   Fas↑, 1,   Mcl-1↓, 1,   p27↑, 2,   survivin↓, 1,  

Protein Folding & ER Stress

CHOP↑, 1,   ER Stress↑, 1,   UPR↑, 1,  

DNA Damage & Repair

P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State

CD44↓, 2,   CSCs↓, 2,   EMT↓, 1,   FOXO3↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   mTOR↓, 2,   PI3K↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   Wnt↓, 1,  

Migration

E-cadherin↑, 1,   MMP2↓, 2,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   Twist↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   Hif1a↓, 2,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

NF-kB↓, 2,   p65↓, 1,  

Hormonal & Nuclear Receptors

AR↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 2,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 5,  

Clinical Biomarkers

AR↓, 1,  
Total Targets: 72

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

Catalase↑, 1,   GSH↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,  

Functional Outcomes

chemoP↑, 1,   toxicity∅, 1,  
Total Targets: 10

Scientific Paper Hit Count for: selectivity, selectivity
5 HydroxyTyrosol
1 Oleuropein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:1110  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page